Aerosol Delivery of Curcumin Reduced Amyloid-β Deposition and Improved Cognitive Performance in a Transgenic Model of Alzheimer’s Disease

McClure, Richard; Ong, Helena; Janve, Vaibhab; Barton, Shawn M; Zhu, Mei-Ying; Li, Bo; Dawes, M. L.; Jerome, W. Gray; Anderson, Adam W.; Massion, Pierre P.; Gore, John C.; Pham, Wellington

doi:10.3233/jad-160289

Cited by 46 publications

(26 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It was also shown that the distribution of curcumin elevated in the brain of mice exposed to its aerosolized form. Also, the aerosolized curcumin decreased the percentage of plaque size in the brain by binding to amyloid plaques (McClure et al, ). The protective effects of curcumin are not restricted to the regulation of Aβ generation and aggregation, and several studies have indicated that curcumin increased the clearance of Aβ.…”

Section: Experimental Studiesmentioning

confidence: 99%

The impact of curcumin and its modified formulations on Alzheimer's disease

Farkhondeh

Samarghandian

Pourbagher‐Shahri

et al. 2019

Journal Cellular Physiology

View full text Add to dashboard Cite

Alzheimer's disease (AD) is a major health problem worldwide, with no effective treatment approach. Curcumin is the main ingredient of turmeric traditionally used in Asian medicine. Several experimental studies have indicated the protective effect of curcumin and its novel formulations in AD. Curcumin has antioxidant, anti‐inflammatory and neurotrophic activities, proposing a strong potential to prevent neurodegenerative diseases. However, there are no sufficient clinical trials to confirm curcumin use in AD patients. Low bioavailability following oral administration of curcumin limits its usage in human. The present study was designed to gather the effects of curcumin and its modified formulations in human and experimental models of AD.

show abstract

Section: Experimental Studiesmentioning

confidence: 99%

The impact of curcumin and its modified formulations on Alzheimer's disease

Farkhondeh

Samarghandian

Pourbagher‐Shahri

et al. 2019

Journal Cellular Physiology

View full text Add to dashboard Cite

show abstract

“…Ng et al, ). Similarly, many studies have found curcumin treatment to reduce amyloid deposition and improve cognitive performance in Alzheimer's disease (AD) animal models (Bassani et al, ; McClure et al, ; Tai et al, ). Animal studies have lent support to the hypothesis that curcumin could improve cognitive functioning and enhance cell proliferation of dentate gyrus in aged animals (Conboy et al, ).…”

Section: Introductionmentioning

confidence: 99%

Curcumin intervention for cognitive function in different types of people: A systematic review and meta‐analysis

Zhu

Mei

Zeng-guo

et al. 2018

Phytotherapy Research

View full text Add to dashboard Cite

Curcumin is a polyphenolic natural compound with diverse and attractive biological activities, which may prevent or ameliorate pathological processes underlying age‐related cognitive decline, dementia, or mood disorders. However, clinical trials and animal studies have yielded conflicting conclusions regarding its effectiveness for cognition in different individuals. The aim of this review is to meta‐analytically assess the effectiveness of curcumin for cognitive function in different types of people. A preliminary search on PubMed, Embase, Web of Science, ClinicalTrials.gov, Cochrane Library, Chinese National Knowledge Infrastructure, and Wanfang Data and China Biology Medicine disc was performed to identify randomized controlled trials investigating the effect of curcumin on cognition. Six clinical trials with a total of 289 subjects met inclusion criteria for this review. We used a random‐effects model to calculate the pooled standardized difference of means (SMD). For older adults who received curcumin, scores on measures of cognitive function (SMD = 0.33, 95% confidence interval [CI] [0.05, 0.62]; p = 0.02), occurrence of adverse events (odds ratio [OR] = 5.59, 95% CI [0.96, 36.80]; p = 0.05), and measures of depression (SMD = −0.29, 95% CI [0.64, 0.05]; p = 0.09) indicated significant memory improvement. In patients with Alzheimer's disease (AD), scores in measures of cognition status (SMD = −0.90, 95% CI [1.48, −0.32]; p = 0.002) indicated that there was a trend for treated subjects to do worse than placebo‐treated subjects on the Mini‐Mental State Examination. The occurrence of adverse events (OR = 0.87, 95% CI [0.10, 7.51]; p = 0.90) was similar to those who received placebo. Due to insufficient data, it was impossible to provide a narrative account of only the outcomes for schizophrenia. Curcumin appears to be more effective in improving cognitive function in the elderly than in improving symptoms of AD and schizophrenia. Curcumin is also safe and tolerated among these individuals. Because of the small number of studies available, a funnel plot or sensitivity analysis was not possible. Further high‐quality trials with larger sample sizes or bioavailability‐improved curcumin formulations may be considered for reliable assessment.

show abstract

“…96 Another study investigating ferulic acidloaded SLNs against neurotoxicity found that ferulic acid can be extensively delivered to brain cells and can thereby prevent oxidation without any toxicity. 103 Curcumin is another potential compound that showed excellent anti-Alzheimeric effect in various in vitro and in vivo studies, [104][105][106][107][108][109][110][111][112] but it showed limitations in its bioavailability through oral delivery with a very low content in the brain, and could not achieve a significant potential effect. Therefore, many recent studies were intended to improve the bioavailability of curcumin to the brain through oral delivery via SLNs.…”

Section: Anti-alzheimer's Effectmentioning

confidence: 99%

Recent developments in solid lipid nanoparticle and surface-modified solid lipid nanoparticle delivery systems for oral delivery of phyto-bioactive compounds in various chronic diseases

Ganesan

Ramalingam

Karthivashan

et al. 2018

IJN

134

View full text Add to dashboard Cite

Solid lipid nanoparticle (SLN) delivery systems have a wide applicability in the delivery of phyto-bioactive compounds to treat various chronic diseases, including diabetes, cancer, obesity and neurodegenerative diseases. The multiple benefits of SLN delivery include improved stability, smaller particle size, leaching prevention and enhanced lymphatic uptake of the bioactive compounds through oral delivery. However, the burst release makes the SLN delivery systems inadequate for the oral delivery of various phyto-bioactive compounds that can treat such chronic diseases. Recently, the surface-modified SLN (SMSLN) was observed to overcome this limitation for oral delivery of phyto-bioactive compounds, and there is growing evidence of an enhanced uptake of curcumin delivered orally via SMSLNs in the brain. This review focuses on different SLN and SMSLN systems that are useful for oral delivery of phyto-bioactive compounds to treat various chronic diseases.

show abstract

Aerosol Delivery of Curcumin Reduced Amyloid-β Deposition and Improved Cognitive Performance in a Transgenic Model of Alzheimer’s Disease

Cited by 46 publications

References 44 publications

The impact of curcumin and its modified formulations on Alzheimer's disease

The impact of curcumin and its modified formulations on Alzheimer's disease

Curcumin intervention for cognitive function in different types of people: A systematic review and meta‐analysis

Recent developments in solid lipid nanoparticle and surface-modified solid lipid nanoparticle delivery systems for oral delivery of phyto-bioactive compounds in various chronic diseases

Contact Info

Product

Resources

About